Lucentis vs PDT: which is more cost-effective?

Article

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.

Please click here to read the abstract.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

Intravitreal cell therapy as protection from degenerations

September 18th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023
© 2023 MJH Life Sciences

All rights reserved.